Skip to Content
Merck
  • A comparison of the efficacy of subcutaneously administered ivermectin, doramectin, and moxidectin against naturally infected Toxocara vitulorum in calves.

A comparison of the efficacy of subcutaneously administered ivermectin, doramectin, and moxidectin against naturally infected Toxocara vitulorum in calves.

Tropical animal health and production (2011-02-26)
Hamza Avcioglu, Ibrahim Balkaya
ABSTRACT

This study was conducted to investigate the efficacy of ivermectin (IVM), doramectin (DRM), and moxidectin (MXD) against Toxocara vitulorum in calves. In the study, 20 calves naturally infected with T. vitulorum were divided into four groups: three different treatment groups (n = 5) and one positive control (n = 5). The animals in each group received either IVM (Baymec®, Bayer), DRM (Dectomax®, Pfizer), or MXD (Cydectin®, Fort Dodge) by subcutaneous injection at a single dose of 0.2 mg/kg. Fecal egg counts were performed on all animals on days 0, 2, 4, 8, 12, and 16 post-treatment. In conclusion, IVM, DRM, and MXD significantly reduced the fecal egg counts on day 8 post-treatment (99.90%, 98.77%, and 99.57%, respectively). After the 12th day, IVM, DRM, and MXD were found to be 100% effective. There was no significant difference in efficacy between the three treatment groups at any of the sampling dates (P > 0.05). No side effects associated with nervous, respiratory, and gastrointestinal systems were observed. This is the first study to evaluate the comparative efficacy of subcutaneous administration of ivermectin, doramectin, and moxidectin against naturally infected T. vitulorum in calves.

MATERIALS
Product Number
Brand
Product Description

Supelco
Doramectin, VETRANAL®, analytical standard